Search academic texts

Information × Registration Number 0210U007822, 0110U004050 , R & D reports Title Generation of therapeutical monoclonal antibodies against mutant forms of FGFR3 receptor. popup.stage_title Head Gorbenko O.M., Registration Date 22-12-2010 Organization Institute of Molecular Biology and Genetics popup.description2 Monoclonal antibodies (MA) against growth factors play an important role in cancer therapy. Scientific and medical outcomes of their effectiveness in fighting cancer have shown some prospects in the application of such antibodies. Current project was designed to create producers of monoclonal antibodies against fibroblast growth factor receptor - FGFR3. Scientific and technical base necessary for making monoclonal antibodies, highly specific to the mutant FGFR3 receptor forms, is created in full. These stable cell lines, baculovirus constructs and modified ELISA method is a powerful and necessary tool in further work focused on the properties of monoclonal antibodies against mutant forms of receptor FGFR3. Monoclonal antibodies can be used for diagnostic purposes and the establishment of therapeutic anticancer agents. It is known that the high expression of this receptor and its increased activity is observed in the cells of certain types of tumors. According to the fact the created antibodies can be used for detection of FGFR3 expression level in tumors of different types by method of immunohistochemical analysis. Moreover, the application with conjugation of cytotoxic agents or radionuclides to monoclonal antibody can target their delivery to the tumor. Certainly further research is needed in this direction. Equally promising is the use of antibodies for research in the study of signal transduction particularly in FGF-induced signaling. Product Description popup.authors Горбенко Олена Миколаївна popup.nrat_date 2020-04-02 Close